Naturally occurring tumor-specific CD8+ T-cell precursors in individuals with and without cancer

Immunology and Cell Biology

Volumn 88, Issue 5, 2010, Pages 575-585

  Karanikas, Vaios ^a   Zamanakou, Maria ^a   Soukou, Faye ^a   Kerenidi, Theodora ^a   Gourgoulianis, Konstantinos I ^a   Germenis, Anastasios E ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

HLA multimers; peptide specific CD8+ T cells; precursor frequency; tumor antigens

Indexed keywords

MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; CELL CLONE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOCYTE CLONE; LYMPHOCYTE FUNCTION; MALE; PRE T LYMPHOCYTE; THERAPY EFFECT; CANCER STAGING; CELL SEPARATION; FLOW CYTOMETRY; IMMUNOLOGY; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; FEMALE; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PRECURSOR CELLS, T-LYMPHOID;

ANIMALIA;

EID: 77954314345     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2010.8     Document Type: Article

References (51)

1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-915.
2. Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D, Liu C, Lesokhin AM, Sahawneh D et al. Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med 2009; 206: 849-866.
3. Badovinac VP, Haring JS, Harty JT. Initial T cell receptor transgenic cell precursor frequency dictates critical aspects of the CD8(+) Tcell response to infection. Immunity 2007; 26: 827-841.
4. Marzo AL, Klonowski KD, Le Bon A, Borrow P, Tough DF, Lefrançois L. Initial T cell frequency dictates memory CD8+ T cell lineage commitment. Nat Immunol 2005; 6: 793-799.
5. Bricard G, Bouzourene H, Martinet O, Rimoldi D, Halkic N, Gil let M et al. Naturally acquired MAGE-A10-and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. J Immunol 2005; 174: 1709-1716.
6. ShangXY, Chen HS, Zhang HG, PangXW, Qiao H, Peng J R et al. The spontaneous CD8 T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients. Clin Cancer Res 2004; 10: 6946-6955.
7. Filaci G, Fravega M, Setti M, Traverso P, Millo E, Fenoglio D et al. Frequency of telomerase-specific CD8+ T lymphocytes in patients with cancer. Blood 2006; 107: 1505-1512.
8. Sato Y, Shomura H, Maeda Y, MineT, Une Y, Akasaka Y et al. Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci 2003; 94: 802-808.
9. Mine T, Gouhara R, Hida N, Imai N, Azuma K, Rikimaru T et al. Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients. Cancer Sci 2003; 94: 548-556.
10. Tanaka S, Harada M, MineT, Noguchi M, Gohara R, Azuma K et al. Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific ctotoxic T-lymphocyte precursors in the periphery. J Immunother 2003; 26: 357-366.
11. Karanikas V, Lurquin C, Colau D, van Baren N, De Smet C, Lethe B et al. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol 2003; 171: 4898-4904.
12. Ichiki Y, Hanagiri T, Takenoyama M, BabaT, FukuyamaT, Nagata Y et al. Tumor specifc expression of survivin-2B in lung cancer as a novel target of immunotherapy. Lung Cancer 2005; 48: 281-289.
13. Hanagiri T, van Baren N, Neyns B, Boon T, Coulie PG. Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1. Cancer Immunol Immunother 2006; 55: 178-184.
14. Zhang HG, Chen HS, Peng JR, Shang XY, Zhang J, Xing Q et al. Specific CD8(+)T cell responses to HLA-A2 restricted MAGE-A3 p271-279 peptide in hepatocellular carcinoma patients without vaccination. Cancer Immunol Immunother 2007; 56: 1945-1954.
15. Karanikas V, Soukou F, Kalala F, Kerenidi T, Grammoustianou ES, Gourgoulianis KI et al. Baseline levels of CD8+ T cells against survivin and survivin-2B in the blood of lung cancer patients and cancer-free individuals. Clin Immunol 2008; 129: 230-240.
16. So T, Hanagiri T, Chapiro J, Colau D, Brasseur F, Yasumoto K et al. Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules. Cancer Immunol Immunother 2007; 56: 259-269.
17. Romero P. Current state of vaccine therapies in non-small-cell lung cancer. Clin Lung Cancer 2008; 9 (Suppl 1): S28-S36.
18. Bolonaki I, Kotsakis A, Papadimitraki E, Aggouraki D, Konsolakis G, Vagia A et al. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J Clin Oncol 2007; 25: 2727-2734.
19. Coulie PG, Karanikas V, Lurquin C, Colau D, Connerotte T, Hanagiri T et al. Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol Rev 2002; 188: 33-42.
20. Chaux P, Vantomme V, Coulie P, Boon T, Van der Bruggen P. Estimation of the frequencies of anti-Mage-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer. Int J Cancer 1998; 77: 538-542.
21. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999; 10: 673-679.
22. Nowak AK, Lake RA, Robinson BW. Combined chemoimmunotherapy of solid tumors: improving vaccines? Adv Drug Deliv Rev 2006; 58: 975-990.
23. Zitvogel L, Apeth L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? J Clin Invest 2008; 118: 1991-2001.
24. Scheffer SR, Nave H, Korangy F, Schlote K, Pabst R, Jaffee EM et al. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J Cancer 2003; 103: 205-211.
25. Dutoit V, Guillaume P, Cerottini JC, Romero P, Valmori D. Dissecting TCR-MHC/peptide complex interactions with A2/peptide multimers incorporating tumor antigen peptide variants: crucial role of interaction kinetics on functional outcomes. Eur J Immunol 2002; 32: 3285-3293.
26. Reynolds SR, Zeleniuch-Jacquotte A, Shapiro RL, Roses DF, Harris MN, Johnston D et al. Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma. Clin Cancer Res 2003; 9: 657-662.
27. Romero P, Cerottini JC, Speiser DE. The human Tcell response to melanoma antigens. Adv Immunol 2006; 92: 187-224.
28. Keogh E, Fikes J, Southwood S, Celis E, Chesnut R, Sette A. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201- binding affinity. J Immunol 2001; 167: 787-796.
29. Groeper C, Gambazzi F, Zajac P, Bubendorf L, Adamina M, Rosenthal R et al. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. Int J Cancer 2007; 120: 337-343.
30. Valmori D, Scheibenbogen C, Dutoit V, Nagorsen D, Asemissen AM, Rubio-Godoy V et al. Circulating tumor reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(\) effector subset exerting ex vivo tumorspecific cytolytic activity. Cancer Res 2002; 62: 1743-1750.
31. Rufer N, Zippelius A, Batard P, Pittet M, Kurth I, Corthesy P et al. Ex-vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood 2003; 102: 1779-1787.
32. Prlic M, Williams MA, Bevan MJ. Requirements for CD8 T-cell priming, memory generation and maintenance. Curr Opin Immunol 2007; 19: 315-319.
33. Ayyoub M, Migliaccio M, Guillaume P, Lienard D, Cerottini JC, Romero P et al. Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. Eur J Immunol 2001; 31: 2642-2651.
34. Valmori D, Gileadi U, Servis C, Dunbar PR, Cerottini JC, Romero P et al. Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. J Exp Med 1999; 189: 895-906.
35. Zhou M, Peng JR, Zhang HG, Wang HX, Zhong ZH, Pan XY et al. Identification of two naturally presented MAGE antigenic peptides from a patient with hepatocellular carcinoma by mass spectrometry. Immunol Lett 2005; 99: 113-121. (Pubitemid 40718942)
36. Effros RB. Role of T lymphocyte replicative senescence in vaccine efficacy. Vaccine 2007; 25: 599-604.
37. Knutson KL, Disis ML, Salazar LG. CD4 regulatory T cells in human cancer pathogen-esis. Cancer Immunol Immunother 2007; 56: 271-285.
38. Whelan JA, Dunbar PR, Price DA, Purbhoo MA, Lechner F, Ogg GS et al. Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent. J Immunol 1999; 163: 4342-4348.
39. Wooldridge L, Lissina A, Cole DK, van den Berg HA, Price DA, Sewell AK. Tricks with tetramers: how to get the most from multimeric peptide-MHC. Immunology 2009; 126: 147-164.
40. Schamel WW, Arechaga I, Risueno RM, van Santen HM, Cabezas P, Risco C et al. Coexistence of multivalent and monovalent TCRs explains high sensitivity and wide range of response. J Exp Med 2005; 202: 493-503.
41. Dutoit V, Guillaume P, Ayyoub M, Hesdorffer CS, Luescher IF, Valmori D. Decreased binding of peptides-MHC class I (pMHC) multimeric complexes to CD8 affects their binding avidity for the TCR but does not significantly impact on pMHC/TCR dissociation rate. J Immunol 2003; 170: 5110-5117.
42. Kieper WC, Burghardt JT, Surh CD. A role for TCR affinity in regulating naive T cell homeostasis. J Immunol 2004; 172: 40-44.
43. Maile R, Siler CA, Kerry SE, Midkiff KE, Collins EJ, Frelinger JA. Peripheral 'CD8 tuning' dynamically modulates the size and responsiveness of an antigen-specific T cell pool in vivo. J Immunol 2005; 174: 619-627.
44. Kroger CJ, Alexander-Miller MA. Dose-dependent modulation of CD8 and functional avidity as a result of peptide encounter. Immunology 2007; 122: 167-178.
45. Pittet MJ, Gati A, Le Gal FA, Bioley G, Guillaume P, de Smedt M et al. Ex vivo characterization of allo-MHC-restricted T cells specific for a single MHC-peptide complex. J Immunol 2006; 176: 2330-2336.
46. Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML et al. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol 2005; 23: 8950-8958.
47. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Perez JM. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem 2007; 7: 3-18.
48. Tseng CW, Hung CF, Alvarez RD, Trimble C, Huh WK, Kim D et al. Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res 2008; 14: 3185-3192.
49. Karanikas V, Tsochas S, Boukas K, Kerenidi T, Nakou M, Dahabreh J et al. Coexpression patterns of tumor-associated antigen genes by non-small cell lung carcinomas: implications for immunotherapy. Cancer Biol Ther 2008; 7: 345-352.
50. Echchakir H, Mami-Chouaib F, Vergnon I, Baurain JF, Karanikas V, Chouaib S et al. A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res 2001; 61: 4078-4083.
51. Karanikas V, Lodding J, Maino VC, McKenzie IF. Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy. Clin Cancer Res 2000; 6: 829-837.